Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Jun
06
Today In Oncology
AML All-Oral Regimen Safe and Eases Treatment Administration Burden
Study Identifies Serious Infection Risks Linked to Antibody-Drug Conjugates
Overall Survival With EBRT in Hepatocellular Carcinoma
SCLC With Brain-Only Progression Original or Substitute Systemic Therapy With or Without Brain Radiotherapy
Five-Year Survival Analysis: Neoadjuvant Trastuzumab-Pertuzumab Plus Endocrine Therapy or Chemotherapy in HR-Positive/HER2-Positive Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo